Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing allogeneic cell replacement therapies to treat serious medical conditions caused by the loss or dysfunction of critical cellular activity. The company operates through its proprietary AlloSCOPE platform, which… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lineage Cell Therapeutics, Inc. does
In the company’s own words
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company developing allogeneic cell replacement therapies to treat serious medical conditions caused by the loss or dysfunction of critical cellular activity. The company operates through its proprietary AlloSCOPE platform, which enables the manufacturing of mature, differentiated replacement cells derived from pluripotent stem cell lines. Rather than administering stem cells directly to patients, Lineage manufactures specialized human cells with anatomical and physiological functions identical to naturally occurring cells, then transplants them to restore or enhance patient function.
The company's pipeline includes multiple programs at varying stages of development. OpRegen, its most clinically advanced asset, is an allogeneic retinal pigmented epithelial cell therapy in Phase 2a development under a worldwide collaboration with F. Hoffmann-La Roche Ltd. and Genentech, Inc. for treating geographic atrophy secondary to dry age-related macular degeneration. OPC1, an allogeneic oligodendrocyte progenitor cell therapy for spinal cord injury, represents the company's most advanced internally owned program and is currently in Phase 1 safety studies with a novel delivery device. Additional programs include ReSonance, an auditory neuron progenitor cell therapy in preclinical development under collaboration with William Demant Invest 2 Aps; ILT1, a research initiative for potential Type 1 Diabetes treatment; RND1, a hypoimmune induced pluripotent stem cell line developed with Factor Biosciences Limited; PNC1, a photoreceptor cell therapy research initiative; and LCT-CON, an undisclosed research program.
Lineage maintains corporate headquarters in Carlsbad, California, and operates a state-of-the-art cGMP manufacturing facility in Jerusalem, Israel, at the Jerusalem Bio Park on the Hadassah University Hospital campus. All current manufacturing operations, including cell banking and product manufacturing, are conducted through the company's subsidiary Cell Cure Neurosciences Ltd. The company has demonstrated the ability to complete cGMP production runs for multiple product candidates and successfully utilized manufactured cells in FDA-cleared clinical trials. The AlloSCOPE platform's application across multiple programs provides operational leverage and cost efficiency in pipeline expansion.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 876343
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lineage Cell Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lineage Cell Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lineage Cell Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lineage Cell Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lineage Cell Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”